Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00251355 · ClinicalTrials.gov registry record · Phase 1
Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00251355 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 40 participants.
The verdict
NCT00251355, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to test a new treatment of pancreatic cancer that cannot be removed by surgery. This treatment is a Phase I dose escalation research study which will combine one drug at increasing doses with a fixed dose of a second drug and radiation therapy. The drug that will be used at increasing doses is gemcitabine whereas 5-fluorouracil will remain the same for all patients.
Interventions
- DRUG Gemcitabine
- DRUG 5-Fluorouracil
- PROCEDURE Radiation Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 1998-01 |
| Est. Completion | 2008-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00251355
The ClinicalTrials.gov registry entry for NCT00251355 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT00251355 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00251355 about?
NCT00251355 is a clinical study titled "Gemcitabine, 5-Fluorouracil, and Radiation Therapy in the Treatment of Non-Metastatic Pancreatic Cancer". The purpose of this study is to test a new treatment of pancreatic cancer that cannot be removed by surgery. This treatment is a Phase I dose escalation research study which will combine one drug at increasing doses with a fixed dose of a second drug and radiation therapy. The drug that will be used...
What is the current status of trial NCT00251355?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 1998-01. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00251355?
The interventions under investigation include: Gemcitabine (DRUG), 5-Fluorouracil (DRUG), Radiation Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00251355?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.